Compare Ascendis Pharma A/S (ASND) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Sirius XM Holdings Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Sirius XM Holdings Inc trades at $30.25 (market cap $10.24B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Sirius XM Holdings Inc pays a 3.55% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | SIRI | |
|---|---|---|
Market Cap | $17.74B | $10.24B |
Sector | Health | Media |
52-Week High | $277.18 | $30.75 |
52-Week Low | $163.32 | $19.92 |
Enterprise Value | $18.11B | $19.91B |
Dividend Yield | — | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SIRI trades at $30.42, down 0.88% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company shows solid fundamentals with a P/E of 12.89, P/B of 0.87, and consistent earnings beats in recent quarters. Recent developments include upcoming Q2 2026 results on July 30, 2026, and inclusion in the S&P MidCap 400 index.
Outlook remains positive with analyst consensus at Buy (58%) and a $31.17 price target. Key opportunities include strong cash flow and dividend yield, while risks involve competitive pressures and high debt levels. The stock offers value characteristics with upside potential near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
